Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02910583
Title Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pharmacyclics LLC.

chronic lymphocytic leukemia/small lymphocytic lymphoma



Ibrutinib + Venetoclax

Age Groups: senior | adult
Covered Countries USA | ITA | ESP

No variant requirements are available.